Related Experiment Video
Updated: Sep 18, 2026

Multiplexed Isothermal Amplification Based Diagnostic Platform to Detect Zika, Chikungunya, and Dengue 1
Published on: March 13, 2018
Development of a potential vaccine against dengue and chikungunya virus co-infection using immunoinformatics and
Sadeeq Ullah1, Junhong Xie1, Caixia Guo2
1Guangdong Provincial Key Laboratory of Medical Immunology and Molecular Diagnostics, The First Dongguan Affiliated Hospital, School of Medical Technology, Guangdong Medical University, Dongguan 523808, China.
Abstract:
Dengue virus (DENV) and chikungunya virus (CHIKV) co-infection poses a growing challenge in regions where both arboviruses co-circulate, highlighting the need for integrated vaccine strategies. Here, we designed a multi-epitope subunit vaccine candidate targeting conserved regions of the DENV NS1 protein and the CHIKV NSP1 protein using an immunoinformatics-based approach. Conserved CTL, HTL, and B-cell epitopes were selected on the basis of antigenicity, safety-related screening, and population coverage, then assembled with immunologically appropriate linkers and an N-terminal human β-defensin-2 adjuvant. The construct displayed favourable physicochemical features and acceptable structural quality after three-dimensional modeling and validation. Docking analysis indicated stable interaction with human TLR4, which was further examined by normal-mode analysis and 100-ns all-atom molecular dynamics simulations performed in AMBER v24 with the ff19SB force field. Trajectory analyses supported conformational stability of the vaccine-TLR4 complex, and MM/GBSA calculations suggested favourable binding energetics. Codon optimization supported expression feasibility in the E. coli pET-28a(+) system. In silico immune simulation further predicted induction of both humoral and cellular immune responses, with increased antibody production and immune-memory development. These results support the proposed construct as a rational candidate for further experimental evaluation toward a vaccine strategy against DENV-CHIKV co-infection.
